Know more about this business than we do? Cool! Please submit any corrections or missing details you may have.
Help us make it rightAcucela Inc. researches, develops and intends to commercialize therapies for unmet or underserved needs in ophthalmology. The Company currently has three product candidates in clinical development: ACU-4429 for dry age-related macular degeneration, rebamipide for dry eye syndrome and OPA-6566 for ocular hypertension and glaucoma, all of which are being co-developed in the United States with...
Acucela was founded in 2010. Acucela specializes in Deaf Or Blind Home. Acucela has 4 employees and estimated revenues of $150,000.00.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide.
If you don't see your business listed on YellowBot, please add your business listing.
YellowBot wants to get your input! If you have a comment, find a bug or think of something neat we should do, let us know.
© 2007-2024 Solfo, Inc. – All rights reserved